Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. [electronic resource]
Producer: 20140818Description: 233-45 p. digitalISSN:- 1557-3265
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Area Under Curve
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Dose-Response Relationship, Drug
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Phosphatidylinositol 3-Kinase -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Quinoxalines -- administration & dosage
- Signal Transduction
- Skin Diseases -- chemically induced
- Sulfonamides -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.